AbbVie Reports Results from the P-III (TEMPO-2) Study of Tavapadon for Parkinson's Disease
Shots:
- AbbVie has reported topline data from the pivotal P-III (TEMPO-2) study assessing the safety, efficacy & tolerability of tavapadon’s flexible-dose (5mg-15mg, QD) vs PBO for treating adults (n=304; 40-80yrs.) with Parkinson's disease
- Study achieved its 1 & 2EPs, showing -10.3 vs -1.2 reduction in Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III combined score & improved motor aspects of experiences in daily living (MDS-UPDRS Part II) at wk.26
- Safety profile aligned with the previous results, with mild to moderate AEs; full data will be highlighted at future conferences. The company is planning NDA submission to the US FDA in 2025
Ref: Abbvie | Image: Abbvie
Related News:- AbbVie Reports the P-II (EMPOWER) Studies Data of Emraclidine for Treating Schizophrenia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
